Extended Ambulatory Monitoring Improves Risk Stratification in Hypertrophic Cardiomyopathy
| Status: | Active, not recruiting |
|---|---|
| Conditions: | High Cholesterol, Cardiology, Orthopedic |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Orthopedics / Podiatry |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 6/29/2018 |
| Start Date: | November 2016 |
| End Date: | December 31, 2018 |
Eligible subjects will wear 4 consecutive external monitoring devices for a total of 28 days
of monitoring.
of monitoring.
Eligible subjects will be monitored with a SEEQ device. The SEEQ device is a patch-like
device that is worn externally on the chest and continuously monitors heart rhythm. Each
device is worn for seven days and replaced with additional devices for a total of 28 days of
monitoring. Subjects will return the SEEQ equipment at the end of the monitoring period.
Subjects will be contacted by telephone or seen at the clinic approximately 60 days from the
first day of monitoring. Information will be gathered about medications and any cardiac
interventions the subject may have had.
Subjects will again be contacted by telephone or seen in the clinic approximately 1 year from
study start. Information will be gathered about general health, changes in medications, and
cardiac interventions or events. Cardiac testing results will be reviewed.
device that is worn externally on the chest and continuously monitors heart rhythm. Each
device is worn for seven days and replaced with additional devices for a total of 28 days of
monitoring. Subjects will return the SEEQ equipment at the end of the monitoring period.
Subjects will be contacted by telephone or seen at the clinic approximately 60 days from the
first day of monitoring. Information will be gathered about medications and any cardiac
interventions the subject may have had.
Subjects will again be contacted by telephone or seen in the clinic approximately 1 year from
study start. Information will be gathered about general health, changes in medications, and
cardiac interventions or events. Cardiac testing results will be reviewed.
Inclusion Criteria:
Clinical diagnosis of HCM Scheduled for routine ambulatory monitoring for risk
stratification Followed at the Chanin T. Mast HCM Center at Morristown Medical Center
Exclusion Criteria:
Prior implantation of an ICD History of persistent/permanent atrial fibrillation (AF)
We found this trial at
1
site
Morristown, New Jersey 07962
Principal Investigator: Martin Maron, MD
Phone: 973-971-4205
Click here to add this to my saved trials
